Shopping Cart
- Remove All
Your shopping cart is currently empty
MK-0752, a γ-secretase inhibitor, reduces Aβ40 production(IC50=5 nM).

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $52 | In Stock | |
| 5 mg | $163 | In Stock | |
| 10 mg | $255 | In Stock | |
| 25 mg | $438 | In Stock | |
| 50 mg | $637 | In Stock | |
| 100 mg | $892 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $179 | In Stock |
| Description | MK-0752, a γ-secretase inhibitor, reduces Aβ40 production(IC50=5 nM). |
| Targets&IC50 | β-Amyloid:5 nM |
| In vitro | In guinea pigs, oral administration of MK-0752 (10-30 mg/kg) resulted in a dose-dependent reduction of Aβ40 in the plasma, brain, and cerebrospinal fluid. Similarly, in monkeys, MK-0752 (240 mg/kg) was capable of reducing the production of Aβ in the brain. |
| In vivo | In human SH-SY5Y cells, MK-0752 significantly reduces Aβ40 in a dose-dependent manner with an IC50 of 5 nM. |
| Kinase Assay | Protein kinase assays : Protein kinase assays are either done in-house by ELISA-based assay methods (Kit, KDR, PDGFRα, and PDGFRβ) or by a radiometric method. In-house ELISA assays used poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates; phosphorylation is then detected using an antiphosphotyrosine antibody conjugated to HRP. The bound antibody is then quantitated using ABTS as the peroxidase substrate by measuring the absorbance at 405/490 nm. All assays uses purified recombinant kinase catalytic domains that are either expressed in insect cells or in bacteria. The Kit and EGFR protein used for in-house assays are prepared internally; other enzymes are obtained. Recombinant Kit protein is expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and is initially purified as a nonphosphorylated (nonactivated) enzyme with a relatively high Km for ATP (400 μM). In some assays, an activated (tyrosine phosphorylated) form of the enzyme is prepared by incubation with 1 mM ATP for 1 hour at 30 °C. The phosphorylated protein is then passed through a desalting column to remove the majority of the ATP and stored at ?80 °C in buffer containing 50% glycerol. The resultant preparation has a considerably higher specific activity and a lower Km for ATP (25 μM) than the initial nonphosphorylated preparation. The inhibition of Kit autophosphorylation by OSI-930 is assayed by incubation of the nonphosphorylated enzyme at 30 °C in the presence of 200 μM ATP and various concentrations of OSI-930. The reaction is stopped by removal of aliquots into SDS-PAGE sample buffer followed by heating to 100 °C for 5 minutes. The degree of phosphorylation of Kit is then determined by immunoblotting for both total Kit and phosphorylated Kit. |
| Molecular Weight | 442.9 |
| Formula | C21H21ClF2O4S |
| Cas No. | 471905-41-6 |
| Smiles | OC(=O)CC[C@H]1CC[C@@](CC1)(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1 |
| Relative Density. | 1.361 g/cm3 |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | H2O: < 1 mg/mL (insoluble or slightly soluble) DMSO: 89 mg/mL (200.95 mM), Sonication is recommended. Ethanol: 45 mg/mL (101.6 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (7.45 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
Ethanol/DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.